ZyVersa Therapeutics annual stock-based compensation
2021
2022
2022
2023
2024
2025
ZyVersa Therapeutics Stock-Based Compensation Growth & History (ZVSA)
ZyVersa Therapeutics's stock-based compensation was $222,831 for fiscal 2025.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $222,831 | −$482,736 | −68.42% |
| 2024 | 2024-12-31 | $705,567 | −$487,396 | −40.86% |
| 2023 | 2023-12-31 | $1.2M | — | — |
| 2022 | 2022-12-31 | $3.5M | −$720,662 | −16.97% |
| 2022 | 2022-12-12 | $3.5M | −$720,662 | −16.97% |
| 2021 | 2021-12-31 | $4.2M | — | — |
ZyVersa Therapeutics quarterly stock-based compensation
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $55,872 | −$98,019 | −63.69% |
| Q4 2025 | 2025-12-31 | $17,353 | −$143,312 | −89.20% |
| Q3 2025 | 2025-09-30 | $73,988 | −$86,677 | −53.95% |
| Q2 2025 | 2025-06-30 | $59,199 | −$101,465 | −63.15% |
| Q1 2025 | 2025-03-31 | $153,891 | −$69,682 | −31.17% |
| Q4 2024 | 2024-12-31 | $160,665 | −$136,050 | −45.85% |
| Q3 2024 | 2024-09-30 | $160,665 | −$82,380 | −33.89% |
| Q2 2024 | 2024-06-30 | $160,664 | −$205,078 | −56.07% |
| Q1 2024 | 2024-03-31 | $223,573 | −$63,888 | −22.22% |
| Q4 2023 | 2023-12-31 | $296,715 | — | — |
| Q3 2023 | 2023-09-30 | $243,045 | −$250,977 | −50.80% |
| Q2 2023 | 2023-06-30 | $365,742 | −$330,198 | −47.45% |
| Q1 2023 | 2023-03-31 | $287,461 | — | — |
| Q3 2022 | 2022-09-30 | $494,022 | — | — |
| Q2 2022 | 2022-06-30 | $695,940 | — | — |
ZyVersa Therapeutics stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, ZyVersa Therapeutics's stock-based compensation decreased from $4.2M to $222,831, a change of −$4.0M. The latest reported quarter, Q1 2026, shows $55,872.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗